Savvy Trades and Investments

[researcher59]

JAZZ +17 to 191 after posting Q4 earnings -

briefing -

Jazz Pharma beats by $0.12, beats on revs; guides FY26 revs in-line (173.83 +0.58) :
Reports Q4 (Dec) earnings of $6.64 per share, excluding non-recurring items, $0.12 better than the FactSet Consensus of $6.52; revenues rose 8.1% year/year to $1.2 bln vs the $1.17 bln FactSet Consensus.
Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA
Co issues in-line guidance for FY26, sees FY26 revs of $4.25-4.50 bln vs. $4.5 bln FactSet Consensus.